Background
Phase 3, multicenter, randomized trial including 480 patients with locoregionally advanced nasopharyngeal carcinoma (stage III-IVA, excluding T3-4N0). Tested whether adding gemcitabine/cisplatin induction chemotherapy to standard concurrent chemoradiotherapy improves outcomes.
Interventions and follow up
Arm A: Gemcitabine 1 g/m2 days 1 & 8 + cisplatin 80 mg/m2 day 1 induction every 3 weeks x3 cycles, then IMRT + cisplatin 100 mg/m2 days 1, 22, 43
Arm B: IMRT + cisplatin 100 mg/m2 days 1, 22, 43
Primary endpoint: Recurrence-free survival (RFS)
Secondary endpoints: OS, distant RFS, safety
mFollow up: 42.7 mo
Arm B: IMRT + cisplatin 100 mg/m2 days 1, 22, 43
Primary endpoint: Recurrence-free survival (RFS)
Secondary endpoints: OS, distant RFS, safety
mFollow up: 42.7 mo
Results
3-yr RFS: 85.3% vs 76.5%; HR 0.51, 95%CI 0.34-0.77, P=.001
3-yr OS: 94.6% vs 90.3%; HR 0.43, 95%CI 0.24-0.77
3-yr distant RFS: 91.5% vs 84.6%
3-yr OS: 94.6% vs 90.3%; HR 0.43, 95%CI 0.24-0.77
3-yr distant RFS: 91.5% vs 84.6%
Adverse events
Overall grade 3-4: 75.7% (induction arm) vs 55.7%
Hematologic: neutropenia 28% vs 10.5%, thrombocytopenia 11% vs 1%, anemia 9% vs 1%
Non-hematologic: nausea/vomiting 23% vs 14%; late toxicities similar between arms
Hematologic: neutropenia 28% vs 10.5%, thrombocytopenia 11% vs 1%, anemia 9% vs 1%
Non-hematologic: nausea/vomiting 23% vs 14%; late toxicities similar between arms
Conclusions
Gemcitabine/cisplatin induction chemotherapy added to standard concurrent chemoradiotherapy significantly improved 3-year recurrence-free and overall survival in locoregionally advanced nasopharyngeal carcinoma, at the cost of increased acute hematologic toxicity.
Key Limitations
Conducted entirely in endemic, EBV-associated nasopharyngeal carcinoma in China, limiting generalizability to non-endemic disease. Open-label design; longer follow-up needed to confirm durable OS benefit and assess late toxicity.
Clinical Context
Established gemcitabine/cisplatin induction followed by concurrent chemoradiotherapy as a preferred regimen for locoregionally advanced nasopharyngeal carcinoma; reflected in ESMO guidance as a recommended induction option.
References